Ed­i­tas Med­i­cine's sci­ence head Al­bright leaves for new job just as biotech gets tri­al clear­ance for sick­le cell ther­a­py

Ed­i­tas Med­i­cine has re­ceived the FDA’s bless­ing to en­ter the clin­ic with its first ex vi­vo cell ther­a­py — but it will do so with­out CSO Charles Al­bright, who is leav­ing his post for the same gig at an ear­ly-stage com­pa­ny.

The FDA clear­ance was an­nounced min­utes af­ter Ed­i­tas shared word of Al­bright’s de­par­ture ear­ly Mon­day morn­ing. The bit­ter­sweet news caused the biotech’s stock $ED­IT to sink more than 12%, with shares hov­er­ing around $79 apiece.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER